Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Carcinoma, Renal Cell 7Melanoma 5Clear-cell metastatic renal cell carcinoma 5Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sjogren's Syndrome 1Scleroderma, Systemic 1Psoriasis 1Prostatic Neoplasms 1Penile Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multiple Sclerosis 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Inflammatory Bowel Diseases 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Endometrial Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 12pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × CTLA-4 Antigen × Clear all
NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 2 Recruiting
112 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡